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Insulin-like growth factor I induces mesangial proliferation and in-
creases mRNA and secretion of collagen. Insulin-like growth factor I
(IGF-1) is a peptide growth factor that is synthesized in cultured mesang-
ial cells and induces hyperplasia. We tested whether incubation with
IGF-1 at concentrations of 7 nM, 70 n, and 350 nM stimulates mesangial
cell extracellular matrix mRNA and protein levels, and whether it
influences mesangial cell growth. Mesangial cells incubated with IGF-1
demonstrated a statistically significant increase in procollagen al(I) (100
13% vs. 147 12%, 154 10%, and 173 21%) and al(IV) (100
9% vs. 112 9%, 125 8%, and 172 28%) mRNA. Furthermore,
IGF-1 also stimulated a statistically significant increment in al(IV)
mRNA in isolated glomeruli when measured by Northern hybridization
and corroborated by in situ hybridization experiments. In addition,
mesangial cells incubated with IGF-1 induced a statistically significant
increase in both secreted and cell associated type I (secreted: 100 5%vs.
127 9%, 148 5%, 178 11%; and cell-associated: 100 19 vs. 132
17%, 198 24%, and 314 17%) and type IV (secreted: 100 9% vs.
138 11%, 192 17%, 379 16%; and cell-associated: 100 8%vs. 139
10%, 206 16%, 310 15%) collagen. Thus, mRNA and collagen
levels increased in a dose dependent fashion after incubation with IGF-1.
Furthermore, IGF-1 stimulated hyperplasia but not hypertrophy in this in
Vitro system. These data suggest that IGF-1 may contribute to glomerular
sclerosis by increasing mesangial matrix production as well as prolifera-
tion.
Glomeruloscierosis is characterized by capillary collapse and by
the accumulation of normal ECM components in the mesangium,
including type IV collagen [1—7], laminin [5—7], and fibronectin
[4], as well as matrix proteins not normally found in the glomer-
ulus, such as type I collagen [5]. Mesangial cell proliferation often
precedes or accompanies mesangial expansion and the develop-
ment of glomerular sclerosis [1, 6, 8]. Mesangial cell hyperplasia
and glomerulosclerosis have been described in models of mesang-
ial proliferative glomerulonephritis [5], in rats with experimental
diabetic nephropathy [9], and in the subtotal nephrectomy model
of focal and segmental glomeruloscierosis in the rat [4].
IGF-1 is a peptide growth factor that is synthesized and
released from many cells and tissues including the liver and
kidneys [10—14]. IGF-1 receptors have been demonstrated in
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cultured glomerular mesangial and epithelial cells, proximal tu-
bule cells, and vascular endothelial cells [15—18]. The distribution
of IGF-1 and IGF-1 receptors in the glomerulus raises the
possibility that glomeruloscierosis is mediated by IGF-1 through
autocrine, paracrine and possibly endocrine modes of action.
Renal IGF-1 levels are increased in some experimental models of
chronic renal failure [19, 20] and IGF-1 has been implicated in
enhancing extracellular matrix synthesis by renal cells [21, 22].
To investigate the effects of IGF-1 on mesangial cells, we
studied changes in extracellular matrix mRNA levels (including
procollagen csl(IV), procollagen al(I), and laminin Bi) and
collagen synthesis in response to IGF-1 in vitro. In addition, we
performed experiments to evaluate whether IGF-1 induces me-
sangial cell hypertrophy, hyperplasia, or both.
Methods
Characterization of glomeruli and mesangial cells
Kidneys were removed from normal male Sprague-Dawley rats
(Charles River Laboratories, Wilmington, MA, USA), weighing
250 to 300 g. The capsule was detached, and the cortex was
separated from the medulla. Minced cortex was passed through 75
j.tm, 106 jsm, and 125 m mesh sieves to obtain isolated glomeruli.
Glomerular isolates were 93 to 97% pure. Mesangial cells were
cultured from isolated glomeruli after incubation in collagenase
and trypsin-EDTA as described [23]. The mesangial cells were
identified by their characteristic stellate appearance in culture and
grew in an overlapping pattern. They were examined by immuno-
fluorescence microscopy [24] for the presence of actin and myosin
(Biomedical Technologies, Cambridge, MA, USA), and Thy-i
antigen [25] and the absence of factor VIII (Synbiotics, San
Diego, CA, USA). The culture medium consisted of RPMI 1640
supplemented with L-glutamine (Mediatech mc, Herndon, VA,
USA), 15% fetal calf serum (FCS; Hyclone Laboratories, Logan,
UT, USA), HEPES 7 mM (GIBCO, Bethesda, MD, USA),
penicillin 100 U/mi, streptomycin 100 U/mI, and amphotericin B
1.25 mg/mi (Irvine Scientific), pH 7.40. The cells were grown in
the absence of insulin.
Preconfluent cells in log phase growth and confluent cells were
studied between passages 4 and 11. Prior to individual experi-
ments, cells were incubated with "quiescent media" (same as
above except for the presence of 0.5% FCS) overnight. Cells were
then incubated for 24 hours in quiescent medium without or with
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the addition of recombinant human IGF-1, at concentrations of 7
nM, 70 nM, or 350 nM (gift from Hans Peter Guler, M.D.,
CIBA-Geigy, Summit, NJ, USA). Subsequently, cells were har-
vested and total RNA or collagens were extracted and analyzed as
described below.
RNA extraction and Northern analysis
Total RNA was isolated after lysis of cells in guanidinium
thiocyanate and extraction in phenol/chloroform as previously
described [261. The quality of the RNA was assessed by: (1)
optical density ratios of the extracted RNAs at 260 nm and 280
nm; and (2) formaldehyde agarose gel electrophoreses showing
intact 28S and 18S RNA bands when the samples were stained
with ethidium bromide and transilluminated by ultraviolet light
[27].
For Northern analysis, 10 micrograms of RNA per sample were
electrophoresed in 1% agarose gels and transferred to nitrocellu-
lose filters (Nitroplus 2000, Micro Separations mc, Westboro,
MA, USA) for 24 hours at 25°C using 20x SSC as the transfer
solution [271. Prehybridization with salmon sperm DNA was
performed for two to three hours followed by hybridization
overnight using 50% formamide with one of several 32P radiola-
beled probes (Multiprime Kit, Amersham, Arlington Heights, IL,
USA). Hybridized filters were washed and exposed to Kodak
XAR film with two Quanta III intensifying screens at —70°C.
Respective mRNAs were quantitated by laser densitometry of
audioradiograms. Group results are expressed as the percent
change in the mean procollagen or laminin Bi mRNA levels
factored for ribosomal 18S mRNA.
cDNA probes
The following probes were utilized: human procollagen al(I)
cDNA probe, HF-677 [28]; mouse procollagen nl(IV) cDNA
probe pPE123 [29]; ribosomal 18S cDNA clone [30] and laminin
Bi cDNA clone, p156 [31]. Northern analysis demonstrated
unique binding of each of the probes with rat mRNA. For pPE 123
and Hf-677 [27], this resulted in binding to mRNA of two
molecular weights (6.8 and 5.9 Kb for the former and 5.8 and 4.8
Kb for the latter). Total RNA hybridized with laminin BI and
ribosomal 18S cDNA probes resulted in single bands at 6.0 Kb
and 1.9 Kb, respectively [30, 31].
In situ hybridization
In situ hybridization was performed on sections of isolated
glomeruli prepared in the following manner. Twenty-four hours
prior to the experiment, isolated glomeruli were incubated with
medium containing 0.5% FCS and then with 0 or 70 nM IGF-1 for
24 hours. Glomeruli were then centrifuged, and the supernatant
culture medium discarded. The glomeruli were fixed with RNAse-
free 4% paraformaldehyde in phosphate buffered saline (PBS),
pH 7.4, rinsed in RNase-free lx PBS, cryoprotected in RNase-
free 15% sucrose-PBS [32], and embedded in OCT compound
(Miles Laboratories, Elkhart, IN, USA). Subsequently, they were
snap frozen in liquid nitrogen, and 6 jm sections were mounted
on glass slides coated with polylysine, 50 tg/ml (ICN Immuno-
biologicals, Irvine, CA, USA). The slides were incubated with
proteinase-K, followed by 4% paraformaldehyde/PBS, rinsed in
PBS with glycine and then 0.2x SSC. The slides were dried and
incubated with prehybridization solution containing 50% form-
amide. Hybridization proceeded with the addition of 35S labeled
procollagen al(IV) sense or antisense RNA probes to a solution
identical to the prehybridization mixture for 22 hours at 42°C. For
generating procollagen al(IV) sense and antisense RNA probes,
the transcription vector pGEM-4Z (Promega Corporation, Mad-
ison, WI, USA) was used, as previously reported [32]. The slides
were washed, dehydrated and developed after seven weeks. They
were counterstained with 0.5% methyl green. Sections were
examined and photographed with a Zeiss Axiophot photomicro-
scope using bright field, dark field, and differential interference
contrast condensers. The pathologist was blinded to the experi-
mental group origin of the sections examined.
Identification and quantitation of collagen types
EL ISA. Cells were dissolved in 5 M guanidine HC1 in 0.1 M Tris,
pH 8.6. Ninety-six-well plates (Corning Glass Works, Corning,
NY, USA) were coated with standard (Collagen type I or IV, 6.25
to 200 ng/mI, Southern Biotechnology Associates, mc, Birming-
ham, AL, USA), conditioned medium or cell lysates, 100 jtl/well
in triplicate or quadruplicate at 4°C for 16 hours. Wells were then
washed three times with washing buffer (0.15 M NaC1, 0.02 M
NaH2PO4, pH 7.3, 0.05% Tween 20) and blocked with 200 gil/well
of 10% normal goat serum in PBS (0.5 M NaCl, 0.04 M NaH2PO4,
pH 7.4) for one hour at room temperature. Wells were washed
once with washing buffer and incubated with biotinylated poly-
clonal goat-anti-Type I or goat anti-Type IV collagen antibody
(Southern Biotechnology), diluted 1:1500 in blocking buffer, 100
pd/well for two hours at room temperature. Wells were washed
five times and then incubated with 100 s.d/well of horseradish
peroxidase-streptavidin (Southern Biotechnology) diluted 1:3000
in blocking buffer for one hour at room temperature. After five
further washes, 100 jtl/well of reaction solution (0.2 M Tris HC1,
0.15 M NaCl, pH 6.0, 0.2% o-phenylenediamine, 0.01% H202) was
added and incubated in the dark for 15 to 60 minutes for color
development. The color reaction was stopped by the addition of
0.1 M sodium sulfite in 4 M H2S04, 50 jil/well, and absorption of
wells were measured in a microplate reader at 492 nm (UV-Max,
Molecular Devices, Menlo Park, CA, USA). Results are expressed
as ng collagen/mg cell protein or as % of the mean control value.
Standard curves are linear (r = 0.996 to 0.999). Cross reactivity of
collagen type I and IV is  1.5%.
3H-thymidine and '4C leucine incorporation
To study the effects of IGF-1 on DNA and total protein
synthesis by mesangial cells, 3H-thymidine and 14C-leucine incor-
poration were measured. Briefly, quiescent mesangial cells were
incubated with medium containing 0.5% FCS without or with
IGF-1 (7 nM, 70 nM, or 350 nM) for 24 hours. Subsequently,
methyl-3H-thymidine, 0.83 LCi/ml and '4C-leucine, 0.42 jiCi/ml
(Amersham; specific activities of 87 Ci/mmol and 315 mCi/mmol,
respectively) were added and the incubation continued for an
additional four hours. Cells were washed with PBS, lysed, and
precipitated with 5% trichloroacetic acid (TCA). Precipitates
were washed with absolute ethanol, and then air dried. The
TCA-precipitable pellet was dissolved in I N NaOH and the 3H
and 14C radioactivity was measured in triplicate by a liquid
scintillation counter. The readings were corrected for the total
protein as quantified by the Lowry method [33], and the data were
expressed as % of the mean control value.
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Identification and quantification of collagen proteins
Statistical analysis
Results are expressed as the mean SEM. Comparisons were
made using Student's t-test; significant results were determined by
P < 0.05.
Results
Mesangial cell characterization
Mesangial cells were identified by their stellate appearance in
culture and growth in an overlapping pattern. Cultured mesangial
cells did not stain positively for Factor VIII. Cultured cells stained
positively for actin, myosin, and Thy 1 antigen.
Procollagen al (I) and al (IV) and laminin mRNA levels
IGF-1 raised procollagen al(I) and al(IV) mRNA levels
significantly at each of the three concentrations, but not laminin
Bi. At an IGF-1 concentration of 7 n, the procollagen al(I)
mRNA levels rose to 147 12% (P < 0.02) compared to controls
(100 13%). At concentrations of 70 n and 350 nM, procollagen
al(I) mRNA levels increased to 154 10% (P < 0.004) and 173
21% (P < 0.01), respectively (Fig. 1). Similarly, IGF-1 at
concentrations of 7, 70, and 350 nM increased procollagen al(IV)
mRNA levels to 112 9%, 125 8% (P = 0.056), and 172
28% (P < 0.03) compared to controls (100 9%), respectively
(Fig. 1). No significant increase in laminin Bi mRNA levels was
observed in mesangial cells incubated with 70 flM IGF-1 (100
10% vs. 123 17%) as compared to controls.
In isolated glomeruli, incubation with 70 flM IGF-1 resulted in
a statistically significant increment in procollagen al(IV) mRNA
(control 100 14% vs. IGF-1, 187 27%, P < 0.01) (Fig. 2). In
situ hybridization studies were performed to qualitatively assess
whether we could identify which subpopulation(s) of glomerular
cells were responsible for the increased amounts of procollagen
al(IV) mRNA detected by the Northern hybridization technique.
Resolution was insufficient to precisely localize the cellular origin
of the mRNA, but semiquantitative scoring of the glomerular
mRNA amounts confirmed the increment in procollagen al(IV)
mRNA previously demonstrated by Northern analysis (Fig. 3).
To assess the change in collagen synthesis in response to IGF-1,
quantification of type I and IV collagen was performed by ELISA
in mesangial cells in log-phase growth prior to confluence. IGF-1
stimulated increases in both types IV and I secreted and cell
associated collagen in a stepwise fashion. IGF-1 at 7, 70, and 350
flM, induced a 38 11% (P < 0.01), 92 17% ((P < 0.0001), and
279 16% (P < 0.0001) increase in secreted immunoreactive
collagen type IV and a 39 10% (P < 0.003), 106 16% (P <
0.0001), and 210 15% (P < 0.0001) increase in cell-associated
type IV collagen after 24 hours of incubation (Fig. 4). In addition,
an IGF-1-induced increase in secreted and cell-associated type I
collagen was observed: 27 9% (P < 0.01), 48 5% (P <
0.0001), 78 11% (P < 0.0001) and 32 17% (P < 0.22), 98
24% (P < 0.004), 214 17% (P < 0.0001) for secreted and
cell-associated fractions, respectively (Fig. 5). Of interest, when
mesangial cells were studied at confluence, IGF-1 at a concentra-
tion of 70 nM still stimulated collagens I and IV in the secreted
and cell-associated fractions [Type I: 100 6% vs. 121 7% (P
= 0.05) and 100 22% vs. 262 42% (P < 0.0002); Type IV: 100
3% vs. 124 4% (P < 0.004) and 100 4% vs. 124 10% (P
< 0.05)], but the effect was somewhat diminished in magnitude,
particularly for Type IV collagen, compared to the effect in
rapidly replicating cells.
3H-thymidine and '4C-leucine incorporation
The effects of IGF-1 on mesangial cell hyperplasia and hyper-
trophy were assessed by the simultaneous measurement of 3H-
thymidine and 14C-leucine incorporation. Tritiated thymidine
incorporation corrected for total protein was increased in cells
incubated with IGF-1 at concentrations of 7 nM, 70 nM, or 350 nM
[100 6% vs. 106 5% (P = NS), 124 6% (P < 0.01), and 160
7% (P < 0.001), respectively; Fig. 6]. An almost identical
increment was observed in '4C-leucine incorporation in these cells
[100 8% vs. 106 5% (P < 0.65), 124 8% (P < 0.04), and
168 8% (P < 0.001); Fig. 6]. The ratio of 14C-leucine to
3H-thymidine incorporation in the control and IGF-1 treated cells
was similar, suggesting that IGF-1 increased proliferation but did
not induce hypertrophy under these experimental conditions.
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Fig. 1. Procollagen al (I) and al(W) mRNA levels in mesangial cells
incubated without (Lii, control) or with IGF-1 at concentrations of 7 (), 70
(•), and 350 () nM for 24 hours (N = 8 in each group). There is a
significant increase in both procollagen al(I) and al(IV) mRNA levels in
the MC treated with IGF-1 compared to the controls. (*P < 0.02 and **
= 0.056)
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Fig. 2. Procollagen al (IV) mRNA levels in isolated glomeruli incubated
without (El) (N = 13) or with (U) (N = 15) 70 niw IGF-1 for 24 hours. There
is a significant increase in procollagen al(IV) mRNA levels in the
glomeruli treated with IGF-1 compared to the controls. (*P < 0.01)
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Fig. 3. cRNA in situ hybridization for
procollagen csl(W) mRNA in isolated glomendi
incubated A) with or B) without IGF-1 for 24
hours (275X). Black grains designating the
presence of procollagen al(IV) mRNA are
more abundant in glomeruli incubated with
IGF-1 compared to controls.
Secreted Cell—associated
Fig. 4. Secreted and cell-associated immunoreactive Type IV collagen levels
in cultured mesangial cells incubated without (Ia, control), (N = 16) or with
IGF-1, at concentrations of 7 nM (N = 16), 70 nM (N = 12), or 350 nM (N
= 16). There is a significant increase in both secreted and cell-associated
Type IV collagen. [(Symbols are as in Fig. 1) * < 0.01; < 0.0001.]
Discussion
These experiments demonstrated that IGF-1 induces a signifi-
cant increase in procollagen cxl(IV) and al(I) mRNA levels in
cultured mesangial cells, while laminin Bi and ribosomal 18S
mRNA levels were not significantly elevated. Quantification of
both collagens performed by ELISA demonstrated a statistically
significant stepwise increment in Type I and Type IV collagen in
both the cell associated and secreted fractions.
The comparable increases in both mRNA levels and collagen
proteins in the IGF-1 treated mesangial cells suggest that IGF-1
may regulate collagen synthesis at the transcriptional level. How-
ever, a small observed discrepancy in mRNA and protein levels
was noted, with the increment in collagen levels exceeding that of
message. These differences are most likely explained by differ-
ences in sensitivity of the respective methodologies for measuring
each and/or variability associated with studies of small sample
size.
IGF-1 also increased mesangial cell proliferation in a dose-
dependent fashion but did not induce hypertrophy, as evidenced
by similar increments in 3H-thymidine and 14C-leucine incorpo-
ration rates in control and IGF-1-treated cells. Since measure-
ments of secreted and cell associated immunoreactive type I and
IV collagens were corrected for total cell protein, an increase in
nhi** nI
Secreted Cell—associated
Fig. 5. Secreted and cell-associated immunoreactive Type I collagen levels in
cultured mesangial cells incubated without (N = 16) or with 7 nM (N = 16),
70 nM (N = 12), or 350 nM (N = 16) IGF-1. There is a significant increase
in both secreted and cell-associated Type I collagen. [(Symbols are as in
Fig. 1) P < 0.01; < 0.0001.]
200
Fig. 6. 14C-leucine and 3H-thymidine incotporation after incubation of
mesangial cells without (N = 9) or with 7 nM (N 8), 70 nM (N = 9), or 350
nM (N = 8) IGF-1. There is a significant increase to a similar degree in
both 14C-leucine and 3H-thymidine incorporation in mesangial cells
incubated with IGF-1. [(Symbols are as in Fig. 1) P < 0.04; <
0.0008.]
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cell number alone could not account for the increment in type I
and IV collagen observed in cells incubated with IGF-1. In freshly
isolated glomeruli, IGF-1 also induced a statistically significant
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increase in procollagen al(IV) mRNA levels. Although qualita-
tive in nature, in situ hybridization of identically treated glomeruli
suggested the presence of subpopulations of glomerular cells
which express increased procollagen al(IV) mRNA levels when
incubated with IGF-1.
IGF-1 is an important growth factor which has been shown to
influence the rate of synthesis of extracellular matrix (ECM)
elements, including Types I and IV collagen, in chondrocytes,
osteoblasts, lung fibroblast, and endothelial cells [34, 35]. Since
mesangial cells have receptors for IGF-1, it is reasonable to
conjecture that IGF-1 may contribute to glomerulosclerosis by
enhancing ECM synthesis in mesangial cells as well. Increases in
renal IGF-1 have been identified in both clinical and experimental
disorders associated with mesangial expansion and glomeruloscle-
rosis including acromegaly [361, experimental diabetic nephropa-
thy [37, 38], and focal sclerosis, both following subtotal renal
ablation in rats [39]. Furthermore, in the latter disorders, the
expanded mesangial matrix is comprised, at least in part, of an
increment in Type IV collagen and the de novo expression of Type
I collagen. By demonstrating both an increase in mesangial
mRNA and protein levels for Type I and IV collagen, our in vitro
experiments support a potential role for IGF-1 in inducing these
changes in vivo.
It should be noted, however, that other published data do not
support a role for IGF-1 in the genesis of glomeruloscierosis. Mice
transgenic for growth hormone develop glomerulosclerosis, while
those transgenic for IGF-1 do not [40]. In the latter animals,
glomerulosclerosis did not develop despite an almost fourfold rise
in serum IGF-1 [40]. Furthermore, young female rats injected
with recombinant IGF-1 for up to 60 days undergo renal hyper-
plasia but do not develop glomerulosclerosis [41]. These data
suggest that circulating IGF-1 is not involved in the development
of glomerulosclerosis. However, it has been previously reported
that female rats presented with the same stimuli do not develop
glomeruloscierosis at the same rate of male rats [7]. In addition,
these data do not exclude the possibility that factors enhancing the
local production of IGF-1 might induce additional autocrine or
paracrine effects at the level of the glomerulus. Alternatively, it is
possible that in vivo, other factors, such as growth factors,
cytokines, or reactive oxygen radicals may be necessary in addition
to elevated levels of IGF-1 for sclerosis to occur.
Biologic effects of growth factors include both proliferation and
hypertrophy, as well as altered matrix synthesis and degradation
[42]. Twice daily injections of rhIGF-1 to young female rats for
one week induced hyperplasia demonstrable by an increase in
kidney/body weight, kidney DNA/protein ratio, mitosis, and pro-
liferating cell nuclear antigen expression [41]. Additional in vivo
studies in experimental disease models in rats, such as unilateral
nephrectomy [39, 43], experimental diabetes [371, high protein
diets, and potassium deficiency have confirmed that elevated renal
IGF-1 levels and compensatory renal growth are often associated.
In the latter models, the initial rapid growth phase results mainly
from hypertrophy but hyperplasia also occurs, often later. This
was particularly well illustrated in both rats with dietary potassium
depletion and in those fed high protein diets [43, 44]. In hypoka-
lemia, renal hypertrophy at three days is followed by hyperplasia
at four days and is preceded by an increase in extractable
immunoreactive whole kidney IGF-1. IGF-1 levels increase 24
hours after potassium depletion and remain elevated for seven
days before returning to baseline levels. Though renal IGF-1
mRNA levels were not demonstrated to be elevated, these
measurements were made in whole kidney, which could obscure
the detection of a more localized increase in mRNA. Enhanced
immunostaining for IGF-1 seen in these potassium-depleted rats
was present in the medullary collecting duct. This pattern of
increased IGF-1 staining is also observed in compensatory renal
hypertrophy in response to unilateral nephrectomy [14, 45]. In
animals receiving high protein diets, elevated renal immunoassay-
able IGF-1 levels as well as hypertrophy and hyperplasia can be
demonstrated at four days post-nephrectomy. Thus, in vivo,
exogenous rhIGF-1 injections stimulate renal hyperplasia in
young rats [41]. Furthermore, in experimental settings where
hypertrophy predominates and hyperplasia is present to a lesser
extent, a contemporaneous relationship to IGF-1 has been dem-
onstrated. These findings suggest that under pathological condi-
tions, a transient increase in renal IGF-1 may provide a signal
capable of initiating renal growth.
Both hypertrophy and hyperplasia have been implicated in the
pathogenesis of glomerulosclerosis. In particular, these features
have been noted in experimental models in which renal IGF-1 is
increased, including diabetic glomerular sclerosis [38] and after
unilateral nephrectomy [39, 46] in the rat. In vivo, under most
conditions, hypertrophy is the predominant feature and hyperpla-
sia a less prominent finding. In contrast, as demonstrated in the
present studies as well as by other investigators, incubation of
mesangial cells with IGF-1 for 24 hours induces a mitogenic
response, but not a hypertrophic response [47, 48]. However, it is
likely that in the complex in vivo glomerular environments,
different local cellular conditions and the presence of other
growth factors modulate cellular responses, thereby contributing
to the final outcome. Thus, the local concentration of IGF-1, the
timing of that exposure and the duration of exposure in the setting
of a cellular environment impacted by altering conditions with
regard to other cytokines and growth factors likely modulate the
expression of cell behavior. Furthermore, our findings relate to
the effects of IGF-1 on mesangial cells, and should not be
construed to imply potentially deleterious effects of insulin via
binding to mesangial IGF-1 receptors. Previous work in our
laboratory showed decreases in tubular procollagen al(IV)m-
RNA levels in association with insulin treatment in diabetic rats
[32].
In summary, this study demonstrates that IGF-1 increases
mesangial cell procollagen al(I) and al(IV) mRNA levels and
increases Types I and IV collagen synthesis in association with
mesangial cell hyperplasia. Our findings further suggest that in
vitro, IGF-1 increases mesangial cell collagen synthesis via a
transcriptional mechanism. In vivo, in glomerular sclerosis, there
is a marked accrual of extracellular matrix. Our data support the
hypothesis that IGF-1 contributes to this process by increasing
extracellular matrix synthesis and mitogenesis, although, other
growth factors, including PDGF, FGF, EGF [49—51] and TGF-13
[52] likely contribute to and modulate local cellular responses.
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